Repeated low-dose g-irradiation (IR) induces thymic lymphoma in mice because of oncogenic mutations propagating from a primitive hematopoietic stem/progenitor cell (HSC) in the bone marrow. It is well known that IR-induced thymic lymphomagenesis is markedly enhanced by p53 deficiency, yet data also indicate that p53-dependent apoptosis can actively drive tumor formation in this model. The latter was recently expounded on by findings from Puma-deficient mice, indicating that loss of this proapoptotic p53 target gene results in protection from IR-induced lymphomagenesis rather than enhanced susceptibility to. Similar to Puma, the transcription factor interferon regulatory factor 5 (Irf5) has been reported as a p53 target gene and is required for DNA damage-induced apoptosis. To date, no studies have been performed to elucidate the in vivo role of IRF5 in tumorigenesis. Given its essential role in DNA damage-induced apoptosis, we explored the tumor suppressor function of IRF5 in IR-induced thymic lymphomagenesis. Somewhat surprisingly, we found that thymic lymphoma development was significantly suppressed in Irf5 À / À mice as compared with wild-type littermates. Suppression was due, in part, to reduced thymocyte and HSC apoptosis, resulting in reduced compensatory proliferation, and reduced replication stress-associated DNA damage. The observed effects were independent of p53 or Puma as these proteins were upregulated in Irf5 À / À mice in response to IR. This study demonstrates an important new role for IRF5 in maintaining HSC homeostasis after IR and supports the non-redundant functions of IRF5, p53 and PUMA in DNA damage-induced lymphomagenesis. We propose that IRF5 may be an attractive target for developing therapeutic agents to ameliorate radiation-induced bone marrow injury.
INTRODUCTION
DNA damage activates cellular responses that promote DNA repair, arrest the cell cycle, induce apoptosis and/or cellular senescence. 1 It is widely believed that these DNA damage responses are required for the maintenance of genomic stability and prevention of tumor development. 2 All of these defense mechanisms depend to a significant extent on the tumor suppressor p53, and the ability of p53 to promote apoptosis in response to DNA damage is considered critical for tumor suppression.
3 DNA damage-induced apoptosis is mediated primarily by the p53 target genes Puma and Noxa, and another BH3-only Bcl-2 family member, Bim, that is not a direct target of p53. 4, 5 Mice lacking p53, Noxa or Bim significantly enhances g-irradiation (IR)-induced thymic lymphomagenesis (IRTL), [6] [7] [8] whereas Puma À / À mice are protected from IRTL development. 8, 9 These data provided intriguing insight into a new paradigm of apoptosis-driven tumorigenesis and the non-redundant functions of PUMA in p53-mediated apoptosis. The transcription factor interferon regulatory factor 5 (Irf5) is another tumor suppressor gene identified as a direct target of p53. 10 Cells lacking Irf5 are resistant from undergoing DNA damage-induced apoptosis, and overexpression of IRF5 sensitizes them to DNA damage-induced apoptosis. [10] [11] [12] Mouse embryonic fibroblasts (MEFs) from Irf5-deficient mice expressing activated Ha-ras have a phenotype similar to that ofp53-deficient MEFs in response to DNA damage, 13 and a human B-cell lymphoma generated to overexpress IRF5 inhibited in vivo tumor formation in nude mice. 11 Notably, results from each of these studies showed that the downstream mediators of IRF5-induced apoptosis are distinct from p53-induced apoptosis. [11] [12] [13] P53, Puma and Noxa levels were normally upregulated in Irf5 À / À MEFs exposed to IR, 13 and IRF5-mediated apoptosis occurred in the absence of p53. 12 Results from microarray analysis of diagnostic samples from patients with chronic B-cell lymphocytic leukemia having mutant p53 or ATM revealed that the transcriptional activation of Irf5 in response to IR was independent of p53, 14 suggesting that in certain cell types Irf5 may not be regulated by p53.
Although all of these data are supportive of IRF5 tumor suppressor function, additional data in primary human tumors and in vivo models of tumor risk and susceptibility are required to confirm that Irf5 is a tumor suppressor gene. Classic tumor suppressor genes are often inactivated on both alleles by multiple mechanisms, including homozygous deletion, heterozygous deletion and mutation, and transcriptional repression by promoter methylation. We initially showed that Irf5 expression was lacking in primary mononuclear cells from patients with chronic lymphocytic leukemia, acute lymphocytic leukemia and acute monocytic leukemia. 11 A subsequent study found a single missense mutation in Irf5, in a small subset of malignant human lymphoid cells, 15 that encoded a dominant-negative IRF5 protein that inhibited the transactivation ability of wild-type IRF5. More recent data from high-throughput sequencing and expression analysis identified a deletion in 7q32.1-q32.2, the region where Irf5 is located, 16 in patients with splenic marginal zone lymphoma. 17, 18 Comparative expression analysis found a significant reduction in Irf5 expression in splenic marginal zone lymphoma with the 7q32 deletion versus non-deleted tumors. 17, 18 To investigate whether IRF5 contributes to in vivo lymphomagenesis, we exposed gene-ablated mice to fractionated low-dose g-IR and monitored thymic lymphoma development over time.
RESULTS

Loss of
À / À and p53 À / À mice were exposed to four weekly doses of 1.75 Gy IR starting at 5 weeks of age. This fractionated dosing elicits thymic lymphoma because of oncogenic mutations, resulting from DNA double-strand breaks. 19, 20 One hundred percent of wt mice (n ¼ 31) developed IRTL within 3-5 months after the last exposure. In contrast, only 17 out of 34 Irf5 À / À mice developed IRTL over the 300-day monitoring period (Figure 1a) ; this was strikingly different than that observed for p53 À / À mice. As expected, p53 À / À mice developed thymic lymphoma with accelerated rate compared with wt mice. A closer examination of Irf5 À / À mice revealed that only two of the irradiated mice had visually detectable thymic lymphoma based on increased thymus weight (Figure 1b) . 
Physical analysis of cohorts of mice shown in (a). Mock-irradiated (wt_con, n ¼ 4; irf5 À / À _con, n ¼ 4) and g-irradiated (wt_IR, n ¼ 12; irf5 À / À _IR, n ¼ 10) littermates were killed B4 months after the last dose of IR. Weights of thymus, whole-body, spleen and lymph nodes were measured and data were analyzed using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). Lines represent the mean ± s.e.m.
A positive IRTL diagnosis in the other 15 mice was based solely on findings from histological studies and fluorescence-activated cell sorter (FACS) analysis of abnormal CD4 þ /CD8 þ T-cell profiles (data not shown). Irradiated wt mice had significantly enlarged thymi, spleen and lymph nodes, as compared with unirradiated wt or irradiated Irf5 À / À mice; no significant difference was observed between unirradiated and irradiated Irf5 À / À mice in any compartment analyzed (Figure 1b) . Taken together, these date indicate that loss of Irf5 suppresses IRTL formation.
Loss of Irf5 prevents IR-induced apoptosis in the thymus and bone marrow Little is known about IRF5 expression and/or function in the thymus. To begin to understand the mechanism by which loss of Irf5 suppresses IRTL formation, we examined thymic IRF5 expression in wt Irf5 þ / þ mice after whole-body IR. Not surprisingly, we found that low-dose (1.75 Gy) and high-dose (5 Gy) IR upregulates IRF5 protein expression in a time-dependent manner ( Figure 2a and data not shown). This is in agreement with previous reports demonstrating that IRF5 is a DNA damage response gene. [10] [11] [12] [13] A detailed analysis of Irf5 expression in purified thymic T-cell populations from irradiated mice revealed a specific upregulation of Irf5 expression in CD4 À CD8 À double-negative (DN) thymocytes (Supplementary Figure 1a) .
Given that others and we have shown that IRF5 is a critical mediator of DNA damage-induced apoptosis, we examined whether loss of Figure 2b) . These data support that IRF5 is a critical mediator of DNA damage-induced apoptosis in the thymus and BM of irradiated mice, as loss of Irf5 provided resistance in these two compartments.
Absence of cellular depletion and decreased DN thymic T cells in irradiated Irf5
À / À mice Thymic CD4CD8 T-cell populations and tissue cellularity were measured as an indication of cellular apoptosis. The predominant population of thymic T cells in young unirradiated mice are CD4 þ CD8 þ double-positive (DP). In wt mice, 18-24 h after exposure to a single dose of 1.75 Gy IR, the DP population decreases and the DN population increases, as compared with unirradiated control mice 9 ( Figure 2d ). In Irf5 À / À mice, although we observed an increase in the percentage of DN in irradiated mice as compared with unirradiated mice, the percentage of DN T cells in the thymus after IR was significantly less than that found in irradiated Irf5 þ / þ littermates ( Figure 2e ). When tissue cellularity was examined 2 days following single exposure, a significant decrease in total thymic and BM cellularity was observed in Irf5 þ / þ mice ( Figure 2f ). A time-course analysis of thymic and BM cellularity after IR supports that IR-induced apoptosis in these two compartments is significantly diminished in Irf5 Figure 3) . Thymic and BM cellularity returned to normal before subsequent IR in mice of both genotypes.
Recruitment of CD11b
þ cells to the thymus in response to IR is reduced in Irf5 À / À mice Another mechanism by which loss of Irf5 may suppress IRTL formation is by reducing immune cell infiltration to the site of primary inflammation-the thymus, thereby reducing an inflammatory response. We have recently shown in a model of chronic inflammation, pristane-induced murine lupus, that loss of Irf5 diminishes the recruitment of monocytes to its primary site of inflammation-the peritoneal cavity, thereby protecting Irf5
mice from developing lupus. 21 In response to acute cell death, it has been shown that large numbers of CD11b þ cells are recruited into the thymus to clear apoptotic thymocytes. 22 The recruitment of CD11b þ eosinophils and neutrophils to the thymus after 1 Gy whole-body IR was found to have the largest impact on the efficiency of apoptotic cell clearance.
To determine whether the observed decrease in IR-induced thymocyte apoptosis and/or maintained thymic cellularity in Irf5 À / À mice is because of enhanced recruitment of CD11b þ inflammatory cells to the thymus, which results in enhanced apoptotic cell clearance, we examined this population of cells in the thymi of unirradiated and irradiated littermates. For the purpose of this study, we gated on CD11b
À cells that are likely to be newly recruited to the thymus in response to a single dose of 1.75 Gy IR ( Figure 3a ). We found a significant reduction in the percentage of CD11b
À cells in the thymi of irradiated Irf5 À / À mice compared with wt mice (Figure 3b) . A closer examination of this cell population revealed a specific reduction in the percentage of eosinophils
being recruited to the thymus of Irf5
À / À mice ( Figure 3c ). These data suggest that the observed reduction in apoptotic thymocytes in irradiated Irf5 À / À mice is a direct effect of loss of IRF5-mediated apoptotic responses and not a result of enhanced recruitment of eosinophils.
Lack of apoptosis and compensatory proliferation in stem/ progenitor cells from irradiated Irf5 À / À mice It is known that IR-triggered apoptosis and cell death in the thymus is generally followed by a burst of proliferation in the thymi of wt mice because of massive mobilization of progenitor cells from the BM and compensatory proliferation within the thymus for repopulation. 9 Previous results have shown that IR-induced lymphomagenesis can be suppressed by the transfer of healthy BM into irradiated recipients or BM shielding, 23 supporting that thymic lymphomas arise from mutated primitive hematopoietic stem/progenitor cells (HSC) in the BM 20 and not mutations in resident thymocytes. Given this, we monitored BM dynamics upon IR by analyzing the HSC-containing lin þ / þ mice to be significantly larger than that in irradiated Irf5
À / À mice ( Figure 4f) ; the BrdU-positive population increased from B20 to B54% in irradiated wt mice and only B20 to B25% in Irf5 À / À mice. These data support that the diminished ability of Irf5-deficient thymocytes and HSC-containing LSK cells undergo IR-induced apoptosis, and cell death results in decreased proliferation and enhanced survival of HSC. 
À / À mice Based on recent data from irradiated Puma À / À mice 8, 9 and findings presented herein, we propose that loss of Irf5 delays IR-induced lymphomagenesis by limiting the compensatory proliferation of stem/progenitor cells that likely trigger replication stress-associated DNA damage. To confirm this, we gated on LSK BM progenitor cells from 1.75 Gy irradiated or mock-irradiated littermates and examined BrdU incorporation as a measure of proliferation, and g-H2AX staining as a measure of replication stress-associated DNA damage (Figure 5a ). Consistently, we observed increased proliferation and replication stress in the LSK population of irradiated wt compared with Irf5 Irf5-mediated lymphomagenesis X Bi et al microscopy after staining BM and LSK cells with antibodies directed toward BrdU, g-H2AX and 53BP1 (Figure 5c ). Interestingly, it is the BM cells that harbor DNA damage, as revealed by g-H2AX staining, which appear to proliferate preferentially. Similar staining patterns for g-H2AX and 53BP1 were found in FACS-sorted LSK cells. We also examined DNA damage in the thymi of littermates at different time points following the fourth cycle of IR. Thymi from unirradiated littermates showed similar low levels of g-H2AX staining (Figure 5d ). In irradiated wt mice, however, we observed a clear increase in the number of g-H2AX-positive cells over time, with more g-H2AX-positive cells being detected in Irf5 þ / þ than Irf5 À / À mice, as early as 3 days post IR (Figures 5d and e) . Not surprisingly, given that Irf5 À / À mice are largely protected from IRTL, we only observed further accumulation of g-H2AX in the thymi of irradiated wt mice over time and no accumulation of g-H2AX-positive cells was observed in the thymi of irradiated Irf5 À / À mice (Figure 5e ). These data support that the loss of Irf5 prevents the accumulation and/or proliferation of replication stress in HSC (and thymocytes), thereby delaying and/or suppressing IRTL formation in Irf5 À / À mice.
DISCUSSION
We demonstrate in this study that loss of Irf5 suppresses IRTL formation. This is in contrast to what we expected given its previously identified tumor suppressor potential(s), [10] [11] [12] [13] 15, 18, 24, 25 its identification as a p53 target gene 10 and its critical role in DNA damage-induced apoptosis, [11] [12] [13] yet is reminiscent of recent data from low-dose irradiated Puma À / À mice. 8, 9 Although loss of Puma provided nearly 100% delay and/or protection from IRTL, 8, 9 loss of Irf5 provided only 50% protection (Figure 1a) , suggesting that these two factors are non-redundant. Indeed, examination of DNA damage response proteins in thymocytes of irradiated mice revealed normal upregulation of both PUMA and p53 in Irf5 Figure 4a) . Bim and Bax levels were also similarly upregulated in irradiated wt and Irf5 À / À thymocytes, whereas p21 levels were decreased in Irf5 À / À thymocytes. Quantitative real-time polymerase chain reaction (qPCR) analysis of p53 target genes Puma, Noxa and p21 gave similar results, showing relatively equal levels of Puma and Noxa transcripts in thymocytes of irradiated wt and Irf5 À / À mice and dramatically decreased levels in p53 À / À thymocytes; p21 transcript levels were decreased in both Irf5 À / À and p53 À / À thymocytes, albeit to different extents (Supplementary Figure 4b) . Data presented herein on Puma and Noxa expression in Irf5 À / À thymocytes is in agreement with the previous findings in Irf5 À / À MEFs, showing normal upregulation of PUMA and Noxa transcripts in response to X-ray IR. 13 With regard to p21 transcript and protein levels detected in irradiated Irf5 À / À thymocytes, the current data are in contrast with transcript data from Irf5 À / À MEFs, yet in agreement with data in a Burkitt's lymphoma cell line, 11 supporting the potential cell-type-specific regulation of p21 expression by IRF5. Previous gene expression analysis in p53-proficient and -deficient cell lines generated to overexpress or repress IRF5 11-13 identified very few overlapping target genes for IRF5 and p53-p21, Bax and Killer/DR5 were the only three overlapping genes identified, and only p21 and DR5 have been confirmed at the promoter level. 11, 26 Of interest, publicly available microarray and ChIP-seq data sets do not include IRF5 as a p53 target gene; 27, 28 however, this may be due, in part, to the cell types being examined. Thus, the current findings support the presence of a distinct IRF5-dependent and p53/PUMA-independent pathway that controls the sensitivity of thymocytes and HSC to IR-induced apoptosis. However, PUMA has also been shown to be a critical regulator of HSC homeostasis after DNA damage, 29, 30 and this function is divergent from p53 as well. Consequently, it will be important in the near future to delineate clearly the distinct and overlapping functions, as well as signaling pathways, regulated by p53, PUMA and IRF5 in HSCs. These types of comparative analyses will have important implications for patients undergoing radiation therapy, as it is well known that patients receiving this type of therapy can develop acute BM injury as a consequence of apoptosis in HSC. 31, 32 The current data provide strong support for the therapeutic targeting of IRF5 and/or PUMA for HSC radioprotection. 8, 9, 30 In addition to regulating DNA damage-induced apoptosis, IRF5 is an important mediator of inflammatory and immune defense responses. IRF5 was originally identified as a mediator of virusinduced type I interferon expression 16 and was later shown to regulate MyD88-dependent Toll-like receptor (TLR) signaling. 33, 34 IRF5 directly regulates the expression of proinflammatory cytokines interferon-a, interleukin-6, tumor necrosis factor-a and interleukin-12. [33] [34] [35] [36] Although suppression of IRTL formation in Irf5 À / À mice may also be because of a dysregulated immune system, no significant difference in the levels of these cytokines was found between the serum of wt and Irf5
À / À mice 6 weeks after receiving fractionated radiation (data not shown). We also examined immune cell recruitment to the thymus of irradiated mice and found a dramatic decrease in the percentage of eosinophils in the thymus of irradiated Irf5 À / À mice (Figure 3c ). The current data suggest that this is a secondary effect due to reduced thymic apoptosis in Irf5 À / À mice since, as recruitment of eosinophils to the thymus of irradiated mice would be expected to impair apoptotic cell clearance rather than enhance it. 22 Interestingly, a recent study by Liu et al. 37 found that hMGB1, Toll-like receptor 4, interleukin-6 and miR-21 expression and/or signaling were elevated in tumors from mice having IRTL; similar to irradiated Irf5 À / À mice, Tlr4 À / À mice were protected from IRTL. These data support that the suppression of IRTL formation in Irf5 À / À mice may also be due to reduced inflammation; however, data from Michalak et al. 8 show that mice lacking myd88 are similarly susceptible to IRTL as wt mice, suggesting that inflammation is only a minor contributor to IRTL. Data thus far indicate that suppression of IRTL formation in Irf5 À / À mice is primarily due to reduced thymocyte and HSC apoptosis, resulting in reduced compensatory proliferation, and reduced replication stress-associated DNA damage in HSC, and not because of an inflammatory component. However, given the central role that IRF5 has in the regulation of both DNA damage-induced apoptosis and inflammation, we cannot exclude the possibility that loss of these two functions together contributes to the partially protective phenotype observed in Irf5 À / À mice. Further studies will be required to differentiate between these functions.
In summary, even though results from this study were unable to support the in vivo tumor suppressor function of IRF5 in IRinduced lymphomagenesis, they provide important support for (1) IRF5 as a critical and non-redundant mediator of DNA damageinduced apoptosis in the thymus and HSC compartment, (2) IRF5 as a new regulator of HSC homeostasis, (3) the model of apoptosis-driven lymphomagenesis 8, 9 and (4) the therapeutic targeting of IRF5 for the management of radiation-induced damage in patients. Ultimately, for a clear understanding of IRF5's role in lymphomagenesis, as well as other cancer types, it will be important to examine tumor susceptibility in a variety of models that trigger tumorigenesis via different mechanisms. Based on data in Ha-ras-transformed Irf5 À / À MEFs, 13 we would expect that loss of Irf5 would enhance lymphomagenesis in a model driven by oncogene transformation, such as in Em-Myc transgenic mice. 38, 39 Studies such as these are currently underway.
MATERIALS AND METHODS Mice
Irf5 À / À mice in a C57Bl/6 background were described previously. 21, 33, 36 Wild-type C57Bl/6 and p53 À / À mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Backcrossed Irf5 þ / À were intercrossed to obtain a cohort of Irf5 þ / þ and Irf5 þ / þ mice were used as controls. The Dock2 mutation was analyzed by PCR genotyping of purified RNA from peripheral blood mononuclear cells of Irf5 þ / þ and Irf5 À / À littermates. 40 All Irf5
and Irf5 À / À littermates used in this study expressed wild-type Dock2 alleles. In some cases, mice were injected with BrdU (1 mg per mouse in 100 ml) and killed 45 min later to collect thymus and BM for flow cytometry or immunofluorescence, as described below. All experimental procedures were approved by the Institutional Animal Care and Use Committee at the University of Medicine and Dentistry of New Jersey, New Jersey Medical School.
Thymic lymphoma induction
Mice were subjected to four weekly doses of IR with 1.75 Gy from a Mark I Cesium-137 source starting at 5 weeks of age. Mice were monitored in a pathogen-free animal facility for 300 days for signs of illness, and tumor onset was calculated from the last dose of g-IR. A thymic mass 450 mg, comprising an abnormal CD4 þ /CD8 þ T-cell FACS profile and/or independent diagnosis by a pathologist, was considered a thymic lymphoma.
Western blotting and quantitative real-time PCR Western blot analysis was performed to determine protein expression 24 in primary thymocytes. Proteins were detected with polyclonal anti-IRF5, antib-actin, anti-p21, anti-Bax, anti-Bim, anti-PUMA and anti-p53 antibodies from Cell Signaling Technology (Danvers, MA, USA). Quantitative real-time PCR analysis of IRF5, Noxa, PUMA, p21 and GAPDH transcript levels was performed as described previously. 13, 36 Flow cytometry and cell sorting FACS analysis of cell subset composition of thymus and BM was performed. Briefly, BM cells were collected from both femurs and tibias and thymocytes by homogenizing. Cells were stained with FITC-coupled Annexin V plus PI and fluorochrome-labeled antibodies against CD4, CD8, CD3, CD45, CD11b, CD11c, lin, c-kit, Sca-1, Siglec-F and F4/80 (Biolegend, San Diego, CA, USA) for 20 min and washed with red blood cell lysis buffer for 5 min. Cells were fixed with 2% formaldehyde in phosphate-buffered saline for up to 12 h. Intracellular BrdU staining was performed using the BrdU labeling kit APC (BD Biosciences, San Jose, CA, USA) following the manufacturer's instruction; cells were stained with anti-BrdU (BD Biosciences), anti-g-H2AX (Cell Signaling) and anti-pH3 (Biolegend). Samples were acquired on a FACS Calibur and data analyzed using FlowJo (Tree Star, Ashland, OR, USA). Thymocytes from mock-irradiated or 1.75 Gy irradiated mice were sorted on a BD FACSVantage SE (BD Biosciences) into four subsets (CD4 þ CD8 þ , DP; CD4 À CD8 À , DN; CD4 þ CD8 À and CD4 À CD8 þ , SP) for RNA isolation and quantitative real-time PCR analysis of Irf5 expression. Similarly, LSK BM progenitor cells were FACS sorted from total BM 8, 9 for immunofluorescence analysis on slides.
